Vincent Deramo, MD
Ophthalmology · Great Neck, NYNPI 1073626388
Payments from drug & device makers
Across 130 payments — averaging $835.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hexal AG$105K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$775
- Genentech USA, Inc.$597
- Coherus Oncology, Inc.$360
- Apellis Pharmaceuticals, Inc.$246
- plus $451 from 7 others
What the payments were for
- Food & beverage$2,770100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hexal AG | 14 | $104,902 |
| AbbVie(2 entities) | 20 | $1,241 |
| Regeneron Healthcare Solutions, Inc. | 31 | $775 |
| Genentech USA, Inc. | 31 | $597 |
| Coherus Oncology, Inc. | 12 | $360 |
| Apellis Pharmaceuticals, Inc. | 7 | $246 |
| Mallinckrodt Enterprises LLC | 2 | $154 |
| Mallinckrodt Hospital Products Inc. | 4 | $137 |
| Eyepoint US, Inc. | 2 | $46 |
| Novartis | 3 | $42 |
| Alimera Sciences, Inc. | 2 | $34 |
| Sandoz | 1 | $20 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,571 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 157 | $8,310 |
| Bromfenac Sodium | 46 | $7,043 |
| Ofloxacin | 80 | $1,329 |
| Ketorolac Tromethamine | 23 | $765 |
| Brimonidine Tartrate | 32 | $534 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $356 |
| Latanoprost | 31 | $336 |
| ErythromycinErythromycin Base | 13 | $144 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Great Neck
- Philip FerroneGreat Neck$5.8M
- Jonathan JonischGreat Neck$1M
- Kenneth GrahamGreat Neck$959K
- David RheeGreat Neck$699K
- Brett RosenblattGreat Neck$676K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.